These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. van der Graaff D; Kwanten WJ; Francque SM Med Hypotheses; 2019 Jan; 122():188-197. PubMed ID: 30593409 [TBL] [Abstract][Full Text] [Related]
24. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. Kitade M; Yoshiji H; Kojima H; Ikenaka Y; Noguchi R; Kaji K; Yoshii J; Yanase K; Namisaki T; Yamazaki M; Tsujimoto T; Moriya K; Kawaratani H; Akahane T; Fukui H Mol Med Rep; 2008; 1(4):543-8. PubMed ID: 21479447 [TBL] [Abstract][Full Text] [Related]
26. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related]
27. Decoding cell death signals in liver inflammation. Brenner C; Galluzzi L; Kepp O; Kroemer G J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086 [TBL] [Abstract][Full Text] [Related]
28. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606 [TBL] [Abstract][Full Text] [Related]
29. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Lieber CS Alcohol; 2004 Aug; 34(1):9-19. PubMed ID: 15670660 [TBL] [Abstract][Full Text] [Related]
30. Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Teufel U; Peccerella T; Engelmann G; Bruckner T; Flechtenmacher C; Millonig G; Stickel F; Hoffmann GF; Schirmacher P; Mueller S; Bartsch H; Seitz HK Hepatobiliary Surg Nutr; 2015 Dec; 4(6):426-35. PubMed ID: 26734629 [TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932 [TBL] [Abstract][Full Text] [Related]
32. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327 [TBL] [Abstract][Full Text] [Related]
33. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways. Zhong X; Liu H Biomed Pharmacother; 2018 Feb; 98():111-117. PubMed ID: 29247950 [TBL] [Abstract][Full Text] [Related]
34. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. Meijnikman AS; Herrema H; Scheithauer TPM; Kroon J; Nieuwdorp M; Groen AK JHEP Rep; 2021 Aug; 3(4):100301. PubMed ID: 34113839 [TBL] [Abstract][Full Text] [Related]
35. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application. Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y Front Pharmacol; 2020; 11():601. PubMed ID: 32477116 [TBL] [Abstract][Full Text] [Related]
36. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Su Q; Kumar V; Sud N; Mahato RI Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222 [TBL] [Abstract][Full Text] [Related]
37. Hepatic protein Carbonylation profiles induced by lipid accumulation and oxidative stress for investigating cellular response to non-alcoholic fatty liver disease in vitro. Chienwichai P; Reamtong O; Boonyuen U; Pisitkun T; Somparn P; Tharnpoophasiam P; Worakhunpiset S; Topanurak S Proteome Sci; 2019; 17():1. PubMed ID: 30962768 [TBL] [Abstract][Full Text] [Related]
38. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Maki A; Kono H; Gupta M; Asakawa M; Suzuki T; Matsuda M; Fujii H; Rusyn I Ann Surg Oncol; 2007 Mar; 14(3):1182-90. PubMed ID: 17195915 [TBL] [Abstract][Full Text] [Related]
39. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Linhart KB; Glassen K; Peccerella T; Waldherr R; Linhart H; Bartsch H; Seitz HK Hepatobiliary Surg Nutr; 2015 Apr; 4(2):117-23. PubMed ID: 26005678 [TBL] [Abstract][Full Text] [Related]
40. The role of oxidative stress in non-alcoholic steatohepatitis. Koek GH; Liedorp PR; Bast A Clin Chim Acta; 2011 Jul; 412(15-16):1297-305. PubMed ID: 21514287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]